eravacycline

Description: Eravacycline (formerly known as TP-434 or 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline; trade name: Xerava) is a novel fluorocycline that was evaluated for antimicrobial activity against panels of recently isolated aerobic and anaerobic Gram-negative and Gram-positive bacteria. It was approved by FDA in August 2018 to treat complicated intra-abdominal infections in patients 18 years of age and older. Eravacycline showed potent broad-spectrum activity against 90% of the isolates (MIC90) in each panel at concentrations ranging from <=0.008 to 2 ug/ml for all species panels except those of Pseudomonas aeruginosa and Burkholderia cenocepacia (MIC90 values of 32 ug/ml for both organisms). The antibacterial activity of eravacycline was minimally affected by expression of tetracycline-specific efflux and ribosomal protection mechanisms in clinical isolates. Furthermore, eravacycline was active against multidrug-resistant bacteria, including those expressing extended-spectrum beta-lactamases and mechanisms conferring resistance to other classes of antibiotics, including carbapenem resistance. Eravacycline has the potential to be a promising new intravenous (i.v.)/oral antibiotic for the empirical treatment of complicated hospital/health care infections and moderate-to-severe community-acquired infections.

References: Antimicrob Agents Chemother. 2013 Nov; 57(11):5548-58; Antimicrob Agents Chemother. 2017 Jun 27; 61(7). pii: e00250-17.

Related CAS#:1334714-66-7 (2HCl)